INIS
cancer
100%
reviews
100%
prostate
100%
androgens
100%
central nervous system
100%
therapy
72%
receptors
36%
men
27%
clinical trials
18%
assessments
18%
blood-brain barrier
18%
data
9%
drugs
9%
patients
9%
range
9%
diseases
9%
comparative evaluations
9%
size
9%
synthesis
9%
management
9%
safety
9%
symptoms
9%
output
9%
inclusions
9%
fatigue
9%
acetates
9%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Androgen
100%
Androgen Receptor
42%
Adverse Event
28%
Enzalutamide
28%
Clinical Trial
28%
Incidence
28%
Tolerability
14%
Clinical Study
14%
Complication
14%
Cognitive Defect
14%
Disease Course
14%
Abiraterone Acetate
14%
Drug Safety
14%
Androgen Receptor Antagonist
14%
Apalutamide
14%
Darolutamide
14%
Symptom
14%
Fatigue
14%
Neuroscience
Central Nervous System
100%
Androgen
100%
Cognitive Function
100%
Androgen Receptor
57%
Blood Brain Barrier
28%
Enzalutamide
28%
Receptor Antagonist
14%
Cognitive Disorders
14%
Longitudinal Study
14%
Cognitive Effect
14%